Neuroplasticity in adult human visual cortex

Publication date: Available online 21 February 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Elisa Castaldi, Claudia Lunghi, Maria Concetta MorroneAbstractBetween 1-5:100 people worldwide have never experienced normotypic vision due to a condition called amblyopia, and about 1:4000 suffer from inherited retinal dystrophies that progressively lead to blindness. While a wide range of technologies and therapies are being developed to restore vision, a fundamental question still remains unanswered: would the adult visual brain retain a sufficient plastic potential to learn how to ‘see’ after a prolonged period of abnormal visual experience? In this review we summarize studies showing that the visual brain of sighted adults retains a type of developmental plasticity, called homeostatic plasticity, and this property has been recently exploited successfully for adult amblyopia recovery. Next, we discuss how the brain circuits reorganize when blindness occurs and when visual stimulation is partially restored by means of a ‘bionic eye’ in late blind adults with Retinitis Pigmentosa. The primary visual cortex in these patients slowly became activated by the artificial visual stimulation, indicating that sight restoration therapies can rely on a considerable degree of spared plasticity in adulthood.
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research

Related Links:

Photoreceptor degeneration is a major cause of blindness and a considerable health burden during aging but effective therapeutic or preventive strategies have not so far become readily available. Here we show in mouse models that signaling through the tyrosine kinase receptor KIT protects photoreceptor cells against both light-induced and inherited retinal degeneration. Upon light damage, photoreceptor cells upregulate Kit ligand (KITL) and activate KIT signaling, which in turn induces nuclear accumulation of the transcription factor NRF2 and stimulates the expression of the antioxidant geneHmox1. Conversely, a viableKit m...
Source: eLife - Category: Biomedical Science Tags: Neuroscience Source Type: research
Conclusions: We have reported three new cases with pathogenic variants in PEX6 presenting with milder forms of the Zellweger spectrum disorders (ZSD). The three cases showed distinct clinical features. Thus, expanding the phenotypic spectrum of PBDs and ascertaining exome sequencing is an effective strategy for an accurate diagnosis of clinically overlapping and genetically heterogeneous disorders such as deafness-blindness association. PMID: 32214787 [PubMed - in process]
Source: Molecular Vision - Category: Molecular Biology Tags: Mol Vis Source Type: research
In a clinical trial, gene therapy for X-linked retinitis pigmentosa improved vision.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Editors ' Choice Source Type: research
(University of Helsinki) A canine study carried out at the University of Helsinki has described a gene variant in the regulatory region of the retina resulting in the abnormal function of retinal genes and, eventually, in the loss of vision in dogs. The study can benefit the diagnostics and treatment of retinitis pigmentosa, a disease suffered by two million human beings globally.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
ABSTRACT Degenerative retinal diseases such as retinitis pigmentosa, Stargardt ’ s macular dystrophy, and age-related macular degeneration are characterized by irreversible loss of vision due to direct or indirect photoreceptor damage. No effective treatments exist, but stem cell studies have shown promising results. Our aim with this review was to describe the types of stem cells that are under study, their effects, and the main clinical trials involving them.RESUMO As doen ças degenerativas da retina, como retinose pigmentar, distrofia macular de Stargardt e degeneração macular relaciona &agrav...
Source: Arquivos Brasileiros de Oftalmologia - Category: Opthalmology Source Type: research
by Maria Kaukonen, Ileana B. Quintero, Abdul Kadir Mukarram, Marjo K. Hyt önen, Saila Holopainen, Kaisa Wickström, Kaisa Kyöstilä, Meharji Arumilli, Sari Jalomäki, Carsten O. Daub, Juha Kere, Hannes Lohi, the DoGA Consortium Retinitis pigmentosa (RP) is the leading cause of blindness with nearly two million people affected worldwide. Many genes have been implicated in RP, yet in 30–80% of the RP patients the genetic cause remains unknown. A similar phenotype, progressive retinal atrophy (PRA), affects many dog breed s including the Miniature Schnauzer. We performed clinical, genetic and func...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
Contributors : Huirong Li ; Ling HouSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPhotoreceptor cell degeneration is a major cause of blindness and a considerable health burden during aging but effective therapeutic or preventive strategies have not so far become commercially available. Here we show in mouse models that signaling through the tyrosine kinase receptor KIT protects photoreceptor cells against both light-induced and inherited retinal degeneration. Upon light damage, photoreceptor cells upregulate Kit ligand (KITL) and activate KIT signaling, which in turn induces nuclea...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
RARITAN, NJ, March 2, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene therapy product for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). PRIME is awarded to increase interactions, optimize development plans and accelerate innovative treatments where there is unmet medical need. Similarly, ATMP status is granted to medicines that are based on gene...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionPanel ‐based targeted exome sequencing revealed 23 novel mutations, recognized different combinations forms of variants, and extended the mutational spectrum of retinitis pigmentosa and depicted common variants in northeast China.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Retinitis Pigmentosa (RP) is a clinically and genetically heterogeneous disorder that results in inherited blindness. Despite the large number of genes identified, only ~  60% of cases receive a genetic diagnos...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
More News: Blindness | Brain | Eyes | Learning | Neurology | Neuroscience | Opthalmology | Retinitis Pigmentosa | Study | Universities & Medical Training | Vitamin A